Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 12/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18272380 | 0.91 | PSMB5 (0.42) | PSMB5CAPN1CTSBOPRD1CCKBR | |
| SCHEMBL24091223 | 0.89 | OPRD1 (0.41) | CAPN1CTSBOPRD1CCKBROPRM1 | |
| SCHEMBL16024731 | 0.80 | PSMB5 (0.55) | PSMB5 | |
| SCHEMBL16024773 | 0.80 | PSMB5 (0.55) | PSMB5 | |
| SCHEMBL20097951 | 0.80 | PSMB5 (0.54) | PSMB5TACR1 | |
| SCHEMBL14756691 | 0.80 | PSMB5 (0.54) | PSMB5TACR1 | |
| SCHEMBL14756681 | 0.80 | PSMB5 (0.54) | PSMB5TACR1 | |
| SCHEMBL24091270 | 0.79 | PSMB5 (0.54) | PSMB5 | |
| SCHEMBL24091278 | 0.79 | CCKBR (0.41) | CAPN1CTSBCCKBRTACR1 | |
| SCHEMBL24091220 | 0.75 | PSMB5 (0.49) | PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065339-B2 | FAP-activated proteasome inhibitors for treating solid tumors | TRUSTEES OF TUFTS COLLEGE (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200323994-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | TRUSTEES OF TUFTS COLLEGE | 2020-10-15 | — | — | US | disclosed |
| US-20190054181-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | TRUSTEES OF TUFTS COLLEGE | 2019-02-21 | — | — | US | disclosed |
| US-9956297-B2 | FAP-activated proteasome inhibitors for treating solid tumors | TRUSTEES OF TUFTS COLLEGE (US) | 2018-05-01 | — | — | US | disclosed |
| US-9597410-B2 | FAP-activated proteasome inhibitors for treating solid tumors | TRUSTEES OF TUFTS COLLEGE (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160346401-A1 | FAP-Activated Proteasome Inhibitors for Treating Solid Tumors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-01 | — | — | US | disclosed |
| US-20140255300-A1 | FAP-Activated Proteasome Inhibitors for Treating Solid Tumors | TRUSTEES OF TUFTS COLLEGE (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140255300-A1 | FAP-Activated Proteasome Inhibitors for Treating Solid Tumors | FAP, PSMA1, PSMA6 | PSMB5 15/4885CAPN1 109/4885CTSB 127/4885 |
| US-11065339-B2 | FAP-activated proteasome inhibitors for treating solid tumors | FAP, PSMA1, PSMA6 | PSMB5 15/4885CAPN1 109/4885CTSB 127/4885 |
| US-20160346401-A1 | FAP-Activated Proteasome Inhibitors for Treating Solid Tumors | FAP, PSMA1, PSMA6 | PSMB5 15/4885CAPN1 109/4885CTSB 127/4885 |
| US-20200323994-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | FAP, PSMA1, PSMA6 | PSMB5 15/4885CAPN1 109/4885CTSB 127/4885 |
| US-20190054181-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | FAP, PSMA1, PSMA6 | PSMB5 15/4885CAPN1 109/4885CTSB 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.